How tirzepatide works in the body, step by step

Step 1, what happens in the first minutes after you inject

You inject tirzepatide once a week into the skin of your abdomen, thigh, or upper arm, rotating the site each time. The medicine is absorbed gradually from the subcutaneous tissue into the bloodstream, which is part of why its effects last the full seven days rather than wearing off by Tuesday.

Once circulating, tirzepatide binds to GIP receptors and GLP-1 receptors on cells throughout the body. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are hormones your gut normally releases after eating. Tirzepatide mimics both of them at once, and if you would like a clear explanation of the whole process, our page on how the Mounjaro jab works walks through it from injection to effect. You can read more about the GIP side of this on our page covering how GIP works in tirzepatide, and the broader mechanism is covered in detail on our Mounjaro mechanism page.

For a fuller technical picture of the dual-agonist pharmacology, the BNF's tirzepatide entry is the professional reference UK clinicians use.

Step 2, how the two pathways change how hungry you feel

Most people notice the appetite effect before they notice anything on the scales. Here is what is actually happening.

GLP-1 receptor activation in the hypothalamus (a region of the brain involved in hunger signals) reduces the urge to eat. At the same time, both GLP-1 and GIP action in the gut slows gastric emptying: food stays in your stomach longer, so the physical sensation of fullness lasts well past the meal. Cravings for high-fat, high-calorie foods appear to reduce for many people too, though the exact central-nervous-system mechanism is still being studied.

GIP receptors also exist in fat tissue, and early research suggests GIP agonism may influence how fat cells store and release energy, an effect that is distinct from what GLP-1 alone produces. It is this combination that is thought to explain why tirzepatide's clinical trial results exceeded those of single-pathway GLP-1 medicines in head-to-head testing, as seen in the SURMOUNT-5 trial published in the New England Journal of Medicine in 2025.

If you want to compare how the two mechanisms produce different weight outcomes, the tirzepatide mechanism comparison page sets it out side by side.

Step 3, blood-sugar regulation and why it matters for weight

Both GIP and GLP-1 are incretin hormones, which means they prompt the pancreas to release insulin when glucose is present after a meal. Tirzepatide amplifies this response. Crucially, the effect is glucose-dependent: if blood sugar is already low, the insulin stimulus is minimal, which reduces the risk of hypoglycaemia compared with some older diabetes medicines.

Tirzepatide also suppresses glucagon, the hormone that tells the liver to release stored glucose. Lower glucagon between meals means blood-sugar levels stay steadier, which may also reduce the blood-glucose spikes that can trigger hunger later in the day.

These metabolic effects are part of why tirzepatide holds a dual UK licence: weight management and type 2 diabetes. For weight management specifically, the licensed indication covers adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure or high cholesterol.

The NHS tirzepatide medicines page explains these effects in patient-friendly terms and is worth bookmarking alongside your treatment.

What this means in practice, and how the starting dose fits in

Treatment begins at 2.5 mg. That dose exists so your body adjusts to the new signals gradually; many of the GI side effects people hear about (nausea, loose stools) are the gut adapting to slowed gastric emptying. Starting low and titrating in steps, typically every four weeks, lets most people settle before moving up.

By the time you reach a maintenance dose, the dual-pathway action is doing three things at once: telling your brain you are less hungry, telling your stomach to empty more slowly, and keeping your blood sugar stable so post-meal dips don't send you back to the biscuit tin. That convergence is why many people find the medicine changes their relationship with food in a way that feels different from simply eating less.

If you are curious about how this compares to how Wegovy works, or want to explore the evidence from the SURMOUNT clinical programme, our page on how Mounjaro works in the body goes into the trial data. You can also read more about tirzepatide as a treatment on the tirzepatide overview page.

The weight-loss treatments page is where you can start a free consultation with one of our prescribers, who will review your information the same day, a real clinician, not automated software, checking whether tirzepatide is the right fit for you. Most prescriptions are dispatched the same working day if ordered before 12pm, arriving by DPD the next day in plain packaging. There are no subscriptions; every repeat order is reviewed again before it goes out.

For an overview of the wider weight-loss options we support, including how tirzepatide sits alongside other approaches, see our weight-loss treatment overview. You can also find out more about the clinical team who review consultations on the prescriber profile page.